Christopher Nolan, Odyssey and Oppenheimer

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of ...
Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering ...
U.S. filmmaker Joshua Oppenheimer, now based in Denmark, worries his "home country is perhaps becoming a dictatorship." "It ...
Oppenheimer downgraded Apple from "outperform" to "perform" because it is struggling to adapt to a competitive AI landscape.
(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...
British consumers’ appetite for home entertainment reached new heights in 2024, with the sector surpassing £5.1 billion ($6.4 ...
The card collecting industry has exploded in recent years to such an extent that industry leader Topps is now producing a Robert Oppenheimer card that's ...
Within financials ( XLF ), Wald mentioned capital markets and the SPDR S&P Capital Markets ETF ( KCE) as a top idea, ...
Shares of Apple have surged roughly 40% over the past nine months, but one analyst issued a cautious warning that it’s time to tap the brakes ahead of the company’s earnings report set for Thursday.
Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” ...